Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
暂无分享,去创建一个
R. Maciuca | P. Korenblat | N. Hanania | Karl Yen | S. Fischer | J. Matthews | C. Holweg | J. Corren | Sarah Gray | H. Scheerens | W. Putnam | M. Cheu | Yanan Zheng | M. Noonan | D. Mcclintock | J. Olsson | E. Murray | R. Doyle | Dana E. McClintock
[1] J. Zhu-Shimoni,et al. More similar than different: Host cell protein production using three null CHO cell lines , 2015, Biotechnology and bioengineering.
[2] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[3] N. Jarjour,et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[4] Ruksha Bhadresha. Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.
[5] M. Ultsch,et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. , 2013, Journal of molecular biology.
[6] D. Mosher,et al. α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. , 2013, American journal of respiratory cell and molecular biology.
[7] S. Mosesova,et al. Lebrikizumab Treatment Reduces Serum Periostin Levels In Asthma Patients With Elevated Baseline Levels Of Periostin , 2012, ATS 2012.
[8] Mario Castro,et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2012, American journal of respiratory and critical care medicine.
[9] S. Mosesova,et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.
[10] Nicola A Hanania,et al. Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.
[11] S. Hopkinson,et al. Faculty Opinions recommendation of Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. , 2010 .
[12] S. Muller,et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma , 2010, Proceedings of the National Academy of Sciences.
[13] D. Curran‐Everett,et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.
[14] Barmak Modrek,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.
[15] G. Anderson,et al. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.
[16] I. Pavord,et al. A new perspective on concepts of asthma severity and control , 2008, European Respiratory Journal.
[17] J. Molkentin,et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses , 2008, Mucosal Immunology.
[18] Yee Hwa Yang,et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.
[19] S. Wenzel. Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.
[20] S. Holgate,et al. The mechanisms, diagnosis, and management of severe asthma in adults , 2006, The Lancet.
[21] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[22] Klas Svensson,et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.
[23] E. Juniper,et al. Measuring asthma control. Clinic questionnaire or daily diary? , 2000, American journal of respiratory and critical care medicine.
[24] J L Hankinson,et al. Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.
[25] Third Expert Panel on theDiagnosis,et al. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .
[26] S. Durham,et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. , 1997, The Journal of allergy and clinical immunology.
[27] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[28] M. Lara,et al. Guidelines For The Diagnosis And Management Of Asthma , 1992, The Journal of the American Board of Family Medicine.